We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
- Authors
Miyoshi, Yasuhide; Ohtaka, Mari; Kawahara, Takashi; Ohtake, Shinji; Yasui, Masato; Uemura, Koichi; Yoneyama, Shuko; Yokomizo, Yumiko; Uemura, Hiroji; Miyamoto, Hiroshi; Yao, Masahiro
- Abstract
Introduction: Low-molecular-weight protein tyrosine phosphatase (LMW-PTP) expression affects carcinogenesis in various cancers and has been associated with determining the overall survival among men with metastatic hormone-naïve prostate cancer (mHNPC). In this study, we analyzed the value of LMWPTP for prediction of time to castration-resistant prostate cancer (CRPC) for men with mHNPC. Materials and Methods: We retrospectively enrolled 45 men with mHNPC who were diagnosed from 2003 to 2009. All patients had received androgen deprivation therapy as first-line treatment. Prostate cancer tissues (pre-treatment needle biopsies) were immunohistochemically stained for LMW-PTP. Multivariate analyses (Cox proportional hazard model) were used to correlate baseline clinical factors of age, prostate-specific antigen (PSA), Gleason scores, T stage, N stage, extent of disease on bone scan (EOD), LMW-PTP expression and time to CRPC. Continuous variables were classified as dichotomous. Results: Median age and PSA were 70.0 years and 87.8 ng/mL respectively. Median time to CRPC was 40.2 months. Median time to CRPC was significantly shorter in the high LMW-PTP group (14.8 months) than that in the low LMW-PTP group (86.3 months, p < 0.01). In multivariate analysis, age ≥70 years and high LMW-PTP expression were significant predictors of time to CRPC.
- Subjects
CASTRATION-resistant prostate cancer; PROTEIN-tyrosine phosphatase; PROSTATE cancer treatment; PROSTATE cancer patients; PROTEIN expression; METASTASIS; TUMOR suppressor proteins; HORMONE therapy
- Publication
Urologia Internationalis, 2019, Vol 102, Issue 1, p37
- ISSN
0042-1138
- Publication type
Article
- DOI
10.1159/000493324